President Trump Proposes 100%, 200% Tariffs on Generic Drug Imports: Why It Matters for Indian Pharma

Trump's Generic Drug Tariff Plan

According to Trump's proposal, imported generic medicines will continue to enjoy duty-free access to the US market for the next two years from August 1, 2026. However, beginning in 2028, a 100% tariff would be imposed for one year before increasing further to 200%.

Trump said the policy is intended to encourage pharmaceutical manufacturers to shift production facilities to the United States. Companies would effectively be given a two-year window to establish manufacturing operations domestically before facing significantly higher import duties.

The proposal applies specifically to generic medicines, while policies relating to patented, branded and innovative pharmaceutical products are expected to remain unchanged.

Why the Proposal Matters for Indian Pharmaceutical Companies

US is the largest export market for India's pharmaceutical sector, particularly for generic medicines. Indian drug manufacturers supply a substantial share of affordable medicines consumed across the US healthcare system through products approved by the US Food and Drug Administration (USFDA).

Many leading Indian pharmaceutical companies derive a significant portion of their revenue from the American market. Although the proposed tariffs would not come into effect immediately, they create a medium-term challenge for exporters that rely heavily on US sales.

Drugmakers may eventually have to evaluate several strategic options, including expanding manufacturing capacity in the United States, entering contract manufacturing partnerships or restructuring supply chains to minimise the potential financial impact.

Indian Pharma Firms May Need to Reassess Long-Term Strategy

Building manufacturing facilities in the United States is a complex and capital-intensive process. Apart from substantial investments, companies would also require regulatory approvals, skilled manpower, supply chain infrastructure and compliance with stringent manufacturing standards.

Several large Indian pharmaceutical companies already operate manufacturing or commercial facilities in the US. However, relocating a significant share of production would require considerable time and financial resources, making the two-year transition period particularly important.

The proposal has also raised concerns about its potential impact on medicine prices in the United States.

Generic medicines account for the majority of prescriptions dispensed across the country because they provide affordable alternatives to branded drugs. If import costs rise sharply after the proposed tariffs take effect, pharmaceutical companies may attempt to pass part of the additional cost on to distributors, pharmacies and healthcare providers.

However, the US generic medicines market remains highly competitive, with intense pricing pressure and relatively thin profit margins. This could limit companies' ability to fully pass on higher costs, potentially affecting product availability for certain low-margin medicines.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.